Candesartan plus hydrochlorothiazide fixed combination vs previous monotherapy plus diuretic in poorly controlled essential hypertensive patients

Blood Pressure, Supplement

Volumn 13, Issue 2, 2004, Pages 11-17

  Mancia, Giuseppe ^a   Omboni, Stefano ^b  

^a SAN GERARDO HOSPITAL   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

ACE inhibitors; Antihypertensive treatment; Beta blockers; Calcium antagonists; Candesartan; Essential hypertension; Hydrochlorothiazide

Indexed keywords

ANGIOTENSIN ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CANDESARTAN; CANDESARTAN HEXETIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; BENZIMIDAZOLE DERIVATIVE; TETRAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; ASTHENIA; AUTOMATION; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERURICEMIA; HYPOKALEMIA; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MULTICENTER STUDY; OSCILLOMETRY; OUTPATIENT; PRIORITY JOURNAL; PULSE PRESSURE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; DRUG COMBINATION; HYPERTENSION; MIDDLE AGED; TIME;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BLOOD PRESSURE DETERMINATION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; OSCILLOMETRY; TETRAZOLES; TIME FACTORS;

EID: 10844286334     PISSN: 08038023     EISSN: None     Source Type: Journal    
DOI: 10.1080/08038020410035574     Document Type: Article

References (39)

1. Hansson L, Zanchetti A, Carruthers SG, et al. for the HOT Study Group. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-62.
2. The Heart Outcome Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-53.
3. PROGRESS Collaborative Study Group. Randomised trial of perindopril based blood pressure-lowering regimen among 6108 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-41.
4. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-97.
5. Guidelines Subcommittee of the World Health Organization - International Society of Hypertension (WHO-ISH) Mild Hypertension Liaison Committee. 1999 World Health Organization - International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17: 151-83.
6. Chobanian AV, Bakris GL, Black HR, et al.. the National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VII). JAMA 2003; 289: 2560-72.
7. Guidelines Committee. 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-53.
8. Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs 2002; 62: 443-62.
9. Trenkwalder P. Combination therapy with AT(1)-receptor blockers. J Human Hypertens 2002; 16 Suppl 3: S17-25.
10. Melian EB, Jarvis B. Candesartan cilexetil plus hydrochlorothiazide combination: a review of its use in hypertension. Drugs 2002; 62: 787-816.
11. Oparil S, Levine JH, Zuschke CA, et al.. Effects of candesartan cilexetil in patients with severe systemic hypertension. Candesartan Cilexetil Study Investigators. Am J Cardiol 1999; 84: 289-93.
12. Philipp T, Letzel H, Arens HJ. Dose-finding study of candesartan cilexetil plus hydrochlorothiazide in patients with mild to moderate hypertension. J Human Hypertens 1997; 11 Suppl 2: S67-8.
13. Campbell M, Sonkodi S, Soucek M, Wiecek A. A candesartan cilexetil/hydrochlorothiazide combination tablet provides effective blood pressure control in hypertensive patients inadequately controlled on monotherapy. Clin Exp Hypertens 2001; 23: 345-55.
14. Cuspidi C, Muiesan ML, Valagussa L, et al.. CATCH investigators. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J Hypertens 2002; 20: 2293-300.
15. Ohma KP, Milon, Vaines K. Efficacy and tolerability of a combination tablet of candesartan cilexetil and hydrochlorothiazide in insufficiently controlled primary hypertension - comparison with a combination of losartan and hydrochlorothiazide. Blood Press 2000; 9: 214-20.
16. Koenig W. Comparison of the efficacy and tolerability of combination tablets containing candesartan cilexetil and hydrochlorothiazide or losartan and hydrochlorothiazide in patients with moderate to severe hypertension: results of the CARLOS-Study. Clin Drug Invest 2000; 19: 239-46.
17. Mazzolai L, Burnier M. Comparative safety and tolerability of angiotensin II receptor antagonists. Drug Saf 1999; 21: 23-33.
18. Hansson L, Hedner T, Dahlof B. Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point. Blood Press 1992; 1: 113-19.
19. Asmar R, Lacourcière Y. on behalf of the Candesartan cilexetil in Hypertension Ambulatory Measurement of Blood Pressure (CHAMP) Study Investigators. A new approach to assessing antihypertensive therapy: effect of treatment on pulse pressure. J Hypertens 2000; 18: 1683-90.
20. O'Brien E, Mee F, Atkins N, Thomas M. Evaluation of three devices for self-measurement of blood pressure according to the revised British Hypertension Society Protocol: the Omron HEM-705CP, Philips HP5332, and Nissei DS-175. Blood Press Monit 1996; 1: 55-61.
21. Machin D, Campbell MJ Statistical tables for the design of clinical trials. Blackwell Scientific Publications Boston, 1987.
22. Cohen J Statistical power analysis for the behavioural sciences. Lawrence Erbaum Associates Hillsdale, New Jersey, 1998.
23. Armitage P, Berry G, Matthews JNS Statistical methods in medical research, 4rd edn. Blackwell Scientific Publications Oxford, 2002.
24. Marubini E, Binelli C, Pollini C. Use of linear models for calculation of statistics designed to evaluate the accuracy of analytical methods for pharmaceutical preparations (in Italian). Farmaco 1975; 30: 540-8.
25. Battelli G, Neri G, Rigamonti S. Evaluation of the precision and accuracy of analytical methods for medical specialities using the technique of reconstructed pharmaceutical preparations (in Italian). Farmaco 1976; 31: 638-49.
26. Benetos A, Rudnichi A, Safar M, Guize L. Pulse pressure and cardiovascular mortality in normotensive and hypertensive subjects. Hypertension 1998; 32: 560-4.
27. Millar JA, Lever AF, Burke V. Pulse pressure as a risk factor for cardiovascular events in the MRC Mild Hypertension Trial. J Hypertens 1999; 17: 1065-72.
28. Vaccarino V, Holford TR, Krumholz HM. Pulse pressure and risk for myocardial infarction and heart failure in the elderly. J Am Coll Cardiol 2000; 36: 130-8.
29. Blacher J, Staessen JA, Girerd X, et al.. Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients. Arch Intern Med 2000; 160: 1085-9.
30. Franklin SS, Khan SA, Wong ND, Larson MG, Levy D. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham Heart Study. Circulation 1999; 100: 354-60.
31. Haider AW, Larson MG, Franklin SS, Levy D. Systolic blood pressure, diastolic blood pressure, and pulse pressure as predictor of risk for congestive heart failure in the Framingham Heart Study. Ann Intern Med 2003; 138: 10-16.
32. Ramsay LE, Yeo WW, Jackson PR. Diabetes, impaired glucose tolerance and insulin resistance with diuretics. Eur Heart J 1992; 13 Suppl G: 68-71.
33. Weidmann P, de Courten M, Ferrari P. Effect of diuretics on the plasma lipid profile. Eur Heart J 1992; 13 Suppl G: 61-67.
34. Franse LV, Pahor M, Di Bari M, Shorr RI, Wan JY, Somes GW, Applegate WB. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens 2000; 18: 1149-54.
35. Grobbee DE, Hoes AW. Non-potassium-sparing diuretics and risk of sudden cardiac death. J Hypertens 1995; 13(12 Pt 2): 1539-45.
36. Mancia G, Bertinieri G, Grassi G, et al. Effects of blood pressure measurements by the doctor on the patient's blood pressure and heart rate. Lancet 1983; 2: 695-8.
37. Parati G, Pomidossi G, Casadei R, Mancia G. Lack of alerting reactions and pressor responses to intermittent cuff inflation during non invasive blood pressure monitoring. Hypertension 1985; 7: 597-601.
38. Smith DHG, Neutel JM, Lacourcière Y, Kempthorne-Rawson J. Prospective, randomized, open-label, blinded-endpoint (PROBE) design trials yield the same results as double-blind, placebo-controlled trials with respect to ABPM measurements. J Hypertens 2003; 21: 1291-8.
39. Parati G, Staessen JA. Hypertension drug trials based on ambulatory blood pressure monitoring: when is a double-blind controlled design needed? J Hypertens 2003; 21: 1237-39.